MCID: DFF019
MIFTS: 39

Diffuse Gastric Cancer

Categories: Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Diffuse Gastric Cancer

MalaCards integrated aliases for Diffuse Gastric Cancer:

Name: Diffuse Gastric Cancer 50
Signet Ring Cell Gastric Carcinoma 50
Signet Ring Gastric Carcinoma 50
Gastric Signet Ring Carcinoma 69
Carcinoma, Signet Ring Cell 69
Signet Ring Cell Carcinoma 50
Signet Cell Adenocarcinoma 50

Classifications:



Summaries for Diffuse Gastric Cancer

NIH Rare Diseases : 50 diffuse gastric canceror signet ring cell cancer is a type of cancer found most often in the glandular cells lining the stomach, but can also develop in the bowel, breast, pancreas, bladder, prostate or lung. the 2010 who (world health organization) classification recognizes four major histologic patterns of gastric cancers: tubular, papillary, mucinous and poorly cohesive (including signet ring cell carcinoma), plus uncommon histologic variants. the term "signet ring cell" is often used because the cells look like signet rings when viewed under a microscope. the signet cells are a type of epithelial cell. epithelial tissue is skin tissue, covering and lining the body both inside and out. when diffuse gastric cancer is inherited it is called "hereditary diffuse gastric cancer." treatment depends on the stage at which the cancer is found and may include chemotherapy, radiation therapy, or operations to remove the stomach (gastrectomy). last updated: 2/1/2016

MalaCards based summary : Diffuse Gastric Cancer, also known as signet ring cell gastric carcinoma, is related to gastric cancer risk after h. pylori infection and gastric cancer, somatic. An important gene associated with Diffuse Gastric Cancer is CDH1 (Cadherin 1), and among its related pathways/superpathways are Adhesion and Acetaminophen Pathway (therapeutic doses), Pharmacokinetics. The drugs Vaccines and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and prostate, and related phenotype is neoplasm.

Related Diseases for Diffuse Gastric Cancer

Diseases related to Diffuse Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Related Disease Score Top Affiliating Genes
1 gastric cancer risk after h. pylori infection 34.2 CDH1 CTNNA1
2 gastric cancer, somatic 31.6 CDH1 ERCC1 GSTP1 TGFBR2
3 bile duct signet ring cell carcinoma 12.2
4 signet ring cell adenocarcinoma 11.3
5 pancreatic signet ring cell adenocarcinoma 11.3
6 breast signet ring cell adenocarcinoma 11.3
7 prostate signet ring cell adenocarcinoma 11.3
8 gallbladder signet ring cell adenocarcinoma 11.1
9 ampullary signet ring cell adenocarcinoma 11.1
10 prostate cancer 1 11.1
11 prostate cancer 11.1
12 prostate cancer, hereditary, 12 11.1
13 prostate cancer, hereditary, 13 11.1
14 prostate cancer, hereditary, 2 11.1
15 prostate cancer, hereditary, 11 11.1
16 stomach cancer 10.9
17 familial stomach cancer 10.9
18 ectodermal dysplasia, ectrodactyly, and macular dystrophy 10.6 CDH1 CDH3
19 childhood teratoma of the ovary 10.6 CDH1 CTNNA1
20 pyloric antrum cancer 10.5 CDH1 CTNNA1
21 cavernous hemangioma of face 10.4 CDH1 GSTM1 GSTT1
22 berylliosis 10.3 GSTM1 GSTP1 GSTT1
23 orbital lymphangioma 10.3 CDH1 GSTM1 GSTT1
24 asbestos intoxication 10.3 GSTM1 GSTT1
25 pulmonary fibrosis, idiopathic susceptibility 10.3 CDH1 GSTM1 GSTT1
26 xfe progeroid syndrome 10.1 ERCC1 ERCC2 XRCC3
27 hepatic flexure cancer 10.1 GSTM1 GSTP1 GSTT1
28 zimmermann-laband syndrome 2 10.1 CDH1 GSTM1 GSTP1 GSTT1
29 cerebrooculofacioskeletal syndrome 2 10.1 ERCC1 ERCC2 XRCC3
30 ceroid storage disease 10.1 ERCC1 ERCC2
31 esophagus lymphoma 10.0 CDH1 GSTM1 GSTP1 GSTT1
32 cervical cancer, somatic 10.0 CDH1 GSTM1 GSTP1 GSTT1
33 anemia, hemolytic, rh-null, regulator type 10.0 ERCC1 ERCC2 XRCC3
34 apocrine adenoma 9.9 GSTM1 GSTP1 GSTT1
35 orbital lymphoma 9.9 GSTM1 GSTT1
36 breast cancer 9.9
37 mycetoma 9.8 ERCC2 GSTM1 GSTT1 XRCC3
38 gastric fundus cancer 9.8 CDH1 GSTM1 GSTP1 GSTT1 TGFBR2
39 nail disorder, nonsyndromic congenital, 3, 9.8 CDH1 ERCC1 GSTM1 GSTP1 TGFBR2
40 cleft lip 9.7
41 li-fraumeni syndrome 9.6
42 crohn's disease 9.6
43 pancreatic ductal adenocarcinoma 9.6
44 adenocarcinoma 9.6
45 lynch syndrome 9.6
46 pancreatitis 9.6
47 peritonitis 9.6
48 meckel's diverticulum 9.6
49 cleft lip +/- cleft palate 9.6
50 cleft lip/palate 9.6

Graphical network of the top 20 diseases related to Diffuse Gastric Cancer:



Diseases related to Diffuse Gastric Cancer

Symptoms & Phenotypes for Diffuse Gastric Cancer

MGI Mouse Phenotypes related to Diffuse Gastric Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 CDH1 CTNNA1 DOT1L ERCC1 ERCC2 TGFBR2

Drugs & Therapeutics for Diffuse Gastric Cancer

Drugs for Diffuse Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
3
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
4
Fluorouracil Approved Phase 2, Phase 3, Phase 1 51-21-8 3385
5
Ramucirumab Approved, Investigational Phase 2, Phase 3 947687-13-0
6
Tegafur Approved Phase 3 17902-23-7 5386
7
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
8
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
9
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3 114977-28-5 148124 9877265
10 Antibodies Phase 2, Phase 3
11 Antibodies, Monoclonal Phase 2, Phase 3
12 Antimetabolites Phase 2, Phase 3, Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
14 Immunoglobulins Phase 2, Phase 3
15
s 1 (combination) Phase 3
16 Antimitotic Agents Phase 2, Phase 3
17 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
18 Antidotes Phase 3,Phase 2,Phase 1
19 Calcium, Dietary Phase 3,Phase 2,Phase 1
20 Protective Agents Phase 3,Phase 2,Phase 1
21
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
24
Bevacizumab Approved, Investigational Phase 2 216974-75-3
25
nivolumab Approved Phase 2 946414-94-4
26
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
27
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
28
Sulfamethazine Approved, Vet_approved Phase 1, Phase 2 57-68-1 5327
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
30
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
31
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
32
Alvocidib Experimental, Investigational Phase 2 146426-40-6, 131740-09-5 5287969
33 Alkylating Agents Phase 1, Phase 2
34 Anti-Bacterial Agents Phase 1, Phase 2
35 Antibiotics, Antitubercular Phase 1, Phase 2
36 Mitomycins Phase 1, Phase 2
37 Nucleic Acid Synthesis Inhibitors Phase 1, Phase 2
38 Protein Kinase Inhibitors Phase 2
39 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
40 topoisomerase I inhibitors Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Angiogenesis Inhibitors Phase 2
43 Angiogenesis Modulating Agents Phase 2
44 Analgesics Phase 1, Phase 2
45 Analgesics, Non-Narcotic Phase 1, Phase 2
46 Antirheumatic Agents Phase 1, Phase 2
47 Interleukin-2 Phase 1, Phase 2
48 Peripheral Nervous System Agents Phase 1, Phase 2
49 Micronutrients Phase 2,Phase 1
50 Trace Elements Phase 2,Phase 1

Interventional clinical trials:

(show all 32)

id Name Status NCT ID Phase Drugs
1 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
2 Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases Completed NCT02219529 Phase 3
3 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
4 FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Recruiting NCT02661971 Phase 2, Phase 3 Docetaxel;Oxaliplatin;Calciumfolinat;5-Fluorouracil
5 Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial Active, not recruiting NCT01285557 Phase 3 S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm);Fluorouracil/cisplatin (control arm)
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Terminated NCT00004099 Phase 3 cisplatin;fluorouracil;leucovorin calcium
7 Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients Completed NCT02575859 Phase 1, Phase 2 adjuvant HIPEC
8 Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer Completed NCT01260701 Phase 2 Akt Inhibitor MK2206
9 S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer Completed NCT00103324 Phase 2 lapatinib ditosylate
10 Irinotecan in Treating Patients With Advanced Cancer of the Stomach Completed NCT00003137 Phase 2 irinotecan hydrochloride
11 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Completed NCT00084617 Phase 2 oxaliplatin;irinotecan hydrochloride;capecitabine
12 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach Completed NCT00061932 Phase 2 bortezomib;irinotecan
13 Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Completed NCT00991952 Phase 2 alvocidib;irinotecan hydrochloride
14 Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00084604 Phase 2 irinotecan hydrochloride;cisplatin
15 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
16 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Recruiting NCT02900651 Phase 1, Phase 2 MAK683
17 PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Recruiting NCT03044743 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Interleukin-2
18 Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer Active, not recruiting NCT01212822 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
19 A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer Terminated NCT00064259 Phase 1, Phase 2 cisplatin;fluorouracil
20 A Phase I Trial of AZD3965 in Patients With Advanced Cancer Recruiting NCT01791595 Phase 1 AZD3965
21 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
22 Lauren Classifications and HER2 Status in Gastric Cancer Patients Unknown status NCT01927146
23 Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma Completed NCT01824966
24 Prognosis of Signet Ring Cells in Upper Digestive Neoplasms Completed NCT01249859
25 NBI for Identifying Resection Margin Status in Gastric Cancer Completed NCT02926716
26 Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma Completed NCT02731313
27 Early Onset and Familial Gastric Cancer Registry Recruiting NCT00582257
28 Hereditary Colorectal and Associated Tumor Registry Study Recruiting NCT00633607
29 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer Recruiting NCT01939275
30 Screening for Familial Gastric Cancer in First Degree Relatives Active, not recruiting NCT01727908
31 Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma Active, not recruiting NCT01821196
32 Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer Not yet recruiting NCT02594943

Search NIH Clinical Center for Diffuse Gastric Cancer

Genetic Tests for Diffuse Gastric Cancer

Anatomical Context for Diffuse Gastric Cancer

MalaCards organs/tissues related to Diffuse Gastric Cancer:

39
Breast, Skin, Prostate, Pancreas, Lung, Testes

Publications for Diffuse Gastric Cancer

Articles related to Diffuse Gastric Cancer:

(show top 50) (show all 149)
id Title Authors Year
1
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. ( 28911091 )
2017
2
Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient. ( 28702897 )
2017
3
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. ( 28522256 )
2017
4
Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. ( 28455161 )
2017
5
Telomere length is correlated with mitochondrial DNA copy number in intestinal, but not diffuse, gastric cancer. ( 28693253 )
2017
6
Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer. ( 28476807 )
2017
7
Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. ( 28922362 )
2017
8
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. ( 28460635 )
2017
9
A multidisciplinary approach allows identification of a new pathogenic CDH1 germline missense mutation in a hereditary diffuse gastric cancer family. ( 28487081 )
2017
10
Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. ( 28688938 )
2017
11
Hereditary diffuse gastric cancer in two families: A case report. ( 28789394 )
2017
12
A novel mutation in the CDH1 gene in a Spanish family with hereditary diffuse gastric cancer. ( 27512640 )
2016
13
PanelA testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer. ( 27064202 )
2016
14
The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). ( 27837291 )
2016
15
Cate's Story: Hereditary Diffuse Gastric Cancer. ( 27441520 )
2016
16
An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). ( 27256430 )
2016
17
Early diagnosis of hereditary diffuse gastric cancer: (not only) an endoscopic challenge! ( 27995194 )
2016
18
Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. ( 27573781 )
2016
19
Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer. ( 27909811 )
2016
20
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. ( 27759617 )
2016
21
MicroRNAs in hereditary diffuse gastric cancer. ( 27446532 )
2016
22
Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer. ( 28008412 )
2016
23
Hereditary diffuse gastric cancer--An overview. ( 26150395 )
2015
24
Hereditary diffuse gastric cancer: laparoscopic surgical approach associated to rare mutattion of CDH1 gene. ( 26176257 )
2015
25
Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation. ( 26025002 )
2015
26
Hereditary diffuse gastric cancer: What the clinician should know. ( 26380059 )
2015
27
Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. ( 26072394 )
2015
28
Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. ( 26182300 )
2015
29
[Hereditary diffuse gastric cancer]. ( 25875520 )
2015
30
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. ( 25979631 )
2015
31
Error in Byline. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. ( 26182313 )
2015
32
Recognition of and recent issues in hereditary diffuse gastric cancer. ( 26049741 )
2015
33
Association between Promoter Polymorphisms of TFF1, TFF2, and TFF3 and the Risk of Gastric and Diffuse Gastric Cancers in a Korean Population. ( 26240479 )
2015
34
Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. ( 25576241 )
2015
35
1229: BEYOND HELLP: PERIPARTUM CATASTROPHIC THROMBOEMBOLISM DUE TO HEREDITARY DIFFUSE GASTRIC CANCER. ( 26570890 )
2015
36
CDH1 germ-line missense mutation identified by multigene sequencing in a family with no history of diffuse gastric cancer. ( 25981591 )
2015
37
RhoA mutations identified in diffuse gastric cancer. ( 25026207 )
2014
38
Genetic screening analysis of patients with hereditary diffuse gastric cancer from northern and northeastern Brazil. ( 25180051 )
2014
39
Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study. ( 24389957 )
2014
40
Association between the epithelial cadherin -160C/A gene polymorphism and diffuse gastric cancer risk: a meta-analysis. ( 24615049 )
2014
41
pRb2/p130 is Delocalized in Cytoplasm in Diffuse Gastric Cancer: A Preliminary Study. ( 25205458 )
2014
42
Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. ( 24493355 )
2014
43
Hereditary diffuse gastric cancer associated with E-cadherin germline mutation: a case report. ( 25089230 )
2014
44
Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. ( 24472763 )
2014
45
Detection of CDH1 gene variants in early-onset diffuse gastric cancer in Chinese patients. ( 25648022 )
2014
46
Hereditary diffuse gastric cancer - pathophysiology and clinical management. ( 25439071 )
2014
47
Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. ( 25315765 )
2014
48
Hereditary diffuse gastric cancer: a family diagnosis and treatment. ( 22723466 )
2013
49
Cleft lip, cleft palate, hereditary diffuse gastric cancer and germline mutations in CDH1. ( 23124477 )
2013
50
Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1. ( 24037103 )
2013

Variations for Diffuse Gastric Cancer

Cosmic variations for Diffuse Gastric Cancer:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM18881 APC breast,NS,carcinoma,tubular c.5047G>T p.E1683* 6
2 COSM18876 APC breast,NS,carcinoma,tubular c.3316G>T p.G1106* 6
3 COSM18885 APC breast,NS,carcinoma,tubular c.4495G>T p.G1499* 6
4 COSM18883 APC breast,NS,carcinoma,tubular c.4390G>T p.E1464* 6

Expression for Diffuse Gastric Cancer

Search GEO for disease gene expression data for Diffuse Gastric Cancer.

Pathways for Diffuse Gastric Cancer

GO Terms for Diffuse Gastric Cancer

Cellular components related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell-cell adherens junction GO:0005913 9.33 CDH1 CDH3 CTNNA1
2 catenin complex GO:0016342 8.96 CDH1 CTNNA1
3 flotillin complex GO:0016600 8.62 CDH1 CTNNA1

Biological processes related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.63 CDH1 TGFBR2 XRCC3
2 nucleotide-excision repair, DNA incision, 3-to lesion GO:0006295 9.51 ERCC1 ERCC2
3 glutathione metabolic process GO:0006749 9.5 GSTM1 GSTP1 GSTT1
4 nucleotide-excision repair, preincision complex stabilization GO:0006293 9.49 ERCC1 ERCC2
5 axon regeneration GO:0031103 9.48 CTNNA1 MTR
6 UV protection GO:0009650 9.43 ERCC1 ERCC2
7 t-circle formation GO:0090656 9.4 ERCC1 XRCC3
8 hair cycle process GO:0022405 9.37 CDH3 ERCC2
9 adherens junction organization GO:0034332 9.33 CDH1 CDH3 CTNNA1
10 cellular response to indole-3-methanol GO:0071681 9.26 CDH1 CTNNA1
11 glutathione derivative biosynthetic process GO:1901687 8.8 GSTM1 GSTP1 GSTT1
12 negative regulation of leukocyte proliferation GO:0070664 8.65 GSTP1

Molecular functions related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glutathione peroxidase activity GO:0004602 9.32 GSTP1 GSTT1
2 single-stranded DNA binding GO:0003697 9.26 ERCC1 XRCC3
3 glutathione binding GO:0043295 9.16 GSTM1 GSTP1
4 gamma-catenin binding GO:0045295 8.96 CDH1 CTNNA1
5 glutathione transferase activity GO:0004364 8.8 GSTM1 GSTP1 GSTT1

Sources for Diffuse Gastric Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....